APP and Alzheimer disease: In this study, injection of δ-secretase into hAPP/hMAPT double transgenic mice elicits AD pathologies in the absence of any human patient-derived mutations, supporting that δ-secretase is sufficient to accelerate AD pathogenesis if both human wild-type APP and Tau substrates are sufficient.